BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21359564)

  • 1. Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.
    Kawaguchi T; Kumabe T; Kanamori M; Saito R; Yamashita Y; Sonoda Y; Watanabe M; Tominaga T
    J Neurooncol; 2011 Sep; 104(3):779-87. PubMed ID: 21359564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Primary intracranial malignant germ cell tumor associated with abnormal high value of alpha-fetoprotein and human chorionic gonadotropin].
    Nishiyama K; Nishida K; Kusaka K; Morizumi H
    No Shinkei Geka; 1987 Dec; 15(12):1337-42. PubMed ID: 2452372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary observations for a new treatment in children with primary intracranial yolk sac tumor or embryonal carcinoma. Report of five cases.
    Ushio Y; Kochi M; Kuratsu J; Itoyama Y; Marubayashi T
    J Neurosurg; 1999 Jan; 90(1):133-7. PubMed ID: 10413166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group.
    Kretschmar C; Kleinberg L; Greenberg M; Burger P; Holmes E; Wharam M
    Pediatr Blood Cancer; 2007 Mar; 48(3):285-91. PubMed ID: 16598761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.
    Murphy BA; Motzer RJ; Mazumdar M; Vlamis V; Nisselbaum J; Bajorin D; Bosl GJ
    Cancer; 1994 May; 73(10):2520-6. PubMed ID: 7513603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.
    Goldman S; Bouffet E; Fisher PG; Allen JC; Robertson PL; Chuba PJ; Donahue B; Kretschmar CS; Zhou T; Buxton AB; Pollack IF
    J Clin Oncol; 2015 Aug; 33(22):2464-71. PubMed ID: 26101244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postchemotherapy Residual Tumor Resection in Patients with Elevated Tumor Markers.
    Che Y; Buddensieck C; Albers P; Lusch A; Winter C; Siemer RG; Hiester A
    J Urol; 2022 Mar; 207(3):617-626. PubMed ID: 34694152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case report of a 6-year-old boy with intracranial yolk sac tumor treated by VAB-6 regimen].
    Wada H; Kubo M; Wada T; Ueno Y; Horita S; Ohki T; Munemoto S; Kuroda E; Taguchi H; Muramatsu N
    No Shinkei Geka; 1995 Jan; 23(1):65-8. PubMed ID: 7531296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of alpha-fetoprotein, human chorionic gonadotropin and carcinoembryonic antigen in patients with primary intracranial germ cell tumors.
    Arita N; Ushio Y; Hayakawa T; Uozumi T; Watanabe M; Mori T; Mogami H
    Oncodev Biol Med; 1980; 1(4-5):235-40. PubMed ID: 6169060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of intracranial non-germinomatous germ cell tumors: a retrospective Asian multinational study on treatment strategies and prognostic factors.
    Hong KT; Han JW; Fuji H; Byun HK; Koh KN; Wong RX; Lee HL; Yoon HI; Lee JH; Phi JH; Kim SK; Kim DS; Lyu CJ; Choi JY; Kang HJ; Chen YW; Lee YY; Im HJ; Ra YS; Do Ahn S; Low SYY; Looi WS; Park HJ; Suh YG; Suh CO; Wang KC; Tan EEK; Wong TT; Kim JY
    J Neurooncol; 2022 Oct; 160(1):41-53. PubMed ID: 36045266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
    de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
    Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.
    Wood DP; Herr HW; Motzer RJ; Reuter V; Sogani PC; Morse MJ; Bosl GJ
    Cancer; 1992 Nov; 70(9):2354-7. PubMed ID: 1382832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-fetoprotein and human chorionic gonadotropin in a patient with a primary intracranial germ cell tumor.
    Nørgaard-Pedersen B; Lindholm J; Albrechtsen R; Arends J; Diemer NH; Riishede J
    Cancer; 1978 Jun; 41(6):2315-20. PubMed ID: 77720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of intensive chemotherapy followed by reduced-dose and reduced-field irradiation for intracranial germ cell tumor.
    Takada A; Ii N; Hirayama M; Toyoda H; Matsubara T; Toyomasu Y; Kawamura T; Daimon T; Sakuma H; Nomoto Y
    J Neurosurg Pediatr; 2018 Nov; 23(3):317-324. PubMed ID: 30497152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies.
    Mann JR; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendszus KR
    Cancer; 1989 May; 63(9):1657-67. PubMed ID: 2467734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors.
    Bosl GJ; Head MD
    Int J Biol Markers; 1994; 9(1):25-8. PubMed ID: 7519650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89.
    Calaminus G; Bamberg M; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
    Klin Padiatr; 2004; 216(3):141-9. PubMed ID: 15175958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity.
    Mann JR; Raafat F; Robinson K; Imeson J; Gornall P; Sokal M; Gray E; McKeever P; Hale J; Bailey S; Oakhill A
    J Clin Oncol; 2000 Nov; 18(22):3809-18. PubMed ID: 11078494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.